Ubiquitin: New Frontiers in Signaling and Cellular Regulation

Feb 07–10, 2028 | Keystone Resort, Keystone, CO, United States
Scientific Organizers: David Komander, J. Wade W Harper, and Sonja Lorenz

  Livestream
  In Person
  On Demand
×

-

Feb 07–10, 2028 | Keystone Resort, Keystone, CO, United States

Scientific Organizers: David Komander, J. Wade W Harper, and Sonja Lorenz

Supported by:  
Important Deadlines
Early Registration Deadline: Deadlines not yet available for this meeting.
Scholarship Deadline: Deadlines not yet available for this meeting.
Short Talk Abstract Deadline: Deadlines not yet available for this meeting.
Poster Abstract Deadline: Deadlines not yet available for this meeting.
Meeting Summary

Ubiquitin and ubiquitin-like proteins (UBLs) regulate virtually every aspect of eukaryotic cell biology, and their dysfunction is linked to diseases such as cancer, neurodegeneration, and immune disorders. Despite decades of progress, critical gaps remain in understanding how ubiquitin signals are encoded, decoded, and co-opted in disease.


This Keystone Symposia conference on Ubiquitin: New Frontiers in Signaling and Cellular Regulation will explore themes such as (1) new frontiers in ubiquitin signaling, (2) UBLs, (3) ubiquitination beyond protein substrates, (4) organelle dynamics, (5) emerging tools and methodologies, and (6) insights from animal model systems. Attendees will gain exposure to field-defining discoveries, emerging technologies, and translational frameworks that are reshaping how the field thinks about proteostasis and induced proximity therapies. Interactive sessions and strong industry participation will make this a pivotal forum for scientists seeking to shape the next generation of investigators working at the interface of cell biology and therapeutics of the ubiquitin system.


The conference will convene biochemists, cell biologists, structural scientists, chemical biologists, and clinician-scientists thereby bridging basic and translational communities at a moment when mechanistic discoveries are being rapidly converted into therapeutic opportunity. Held jointly with the Keystone Symposia conference on Induced Proximity: Emerging Technologies and Clinical Translation, joint sessions focused on targeted protein degradation will create rare opportunities for basic scientists and drug developers to align priorities and forge new collaborations.


The ubiquitin field is undergoing a conceptual expansion into non-protein substrates, organelle quality control, and signaling principles across the broader UBL family—research priorities that are not integrated in any other current meeting. Unlike existing meetings that focus narrowly on ubiquitin pathway structural mechanisms, this conference will fuse mechanistic studies with new and emerging biological systems to generate synergy across the ubiquitin landscape. The timeliness of this conference is compelling and offers researchers an unparalleled scientific and strategic opportunity to chart new directions and position their work at the leading edge of this transformation.

Unique Career Development Opportunities

This meeting will feature a Career Roundtable where trainees and early-career investigators will have the opportunity to interact with field leaders from across academic and industry sectors for essential career development advice and networking opportunities. Find out more about Career Roundtables here: https://www.keystonesymposia.org/diversity/career-development-initiatives

KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS

Subscribe for Updates